文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗掌跖脓疱病伴脓疱性关节骨炎52周探索性分析

Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-05-15

本研究为日本掌跖脓疱病(PPP)患者3期随机双盲安慰剂对照试验的探索性分析,评估古塞奇尤单抗在伴脓疱性关节骨炎(PAO)亚组中的疗效。159例PPP患者中66例伴PAO,结果显示古塞奇尤单抗组MRI严重PAO比例从基线23.8%降至52周5.4%,EQ-5D疼痛/不适无或轻微比例从33.3%升至87.5%,CRP平均下降1.71 mg/L。

要点

  • 古塞奇尤单抗可改善PPP伴PAO患者的MRI严重程度和疼痛不适。
  • 52周时EQ-5D疼痛/不适无或轻微者比例从33.3%升至87.5%。
  • CRP平均水平较基线下降1.71 mg/L,提示炎症控制。

核心结论

  • 古塞奇尤单抗治疗日本PPP伴PAO患者52周,对PAO体征和症状显示有益结局。

研究设计与样本

  • 日本PPP患者3期随机双盲安慰剂对照研究的事后探索性分析,159例PPP中66例伴PAO。
  • 患者随机接受古塞奇尤单抗100或200 mg(第0、4、12周及之后每8周)或安慰剂(第16周交叉)。
  • 疗效终点为所有PAO患者至52周的MRI评分、EQ-5D指数评分、EQ-5D疼痛/不适维度评分及CRP水平较基线变化。

主要发现

  • 有所有评估区域MRI数据的PAO患者中,古塞奇尤单抗组严重比例从基线23.8%(10/42)降至52周5.4%(2/42)。
  • 52周EQ-5D指数评分较基线平均变化:伴PAO的PPP患者为0.20(0.17),不伴PAO者为0.15(0.17)。
  • 所有PAO患者中,古塞奇尤单抗组EQ-5D疼痛/不适无或轻微比例从基线33.3%(7/21)升至52周87.5%(35/40)。
  • 所有PAO患者中,古塞奇尤单抗组52周CRP平均水平较基线下降1.71(8.16)mg/L。

临床怎么用

  • 对于PPP伴PAO患者,古塞奇尤单抗可作为改善关节影像学严重程度和疼痛不适的考虑选项。

局限性

  • 本研究为探索性分析,样本量有限(66例PAO),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque-type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP). OBJECTIVE: The aim of this exploratory analysis of a double-blind, multicenter, placebo-controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro-osteitis (PAO). METHODS: Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross-over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL-5 dimensions (EQ-5D) index score, EQ-5D pain/discomfort dimension score and C-reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group. RESULTS: Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ-5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ-5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [-1.71 (8.16) mg/L]. CONCLUSION: Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Yamamoto T, Fukuda K, Morita A, et al. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2020. PMID: 32173916. doi:10.1111/jdv.16355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。